Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea

详细信息	查看全文 | 推荐本文 |

• 作者：Eui-Kyung Lee ; PhD¹ ; ^{ekyung@skku.edu} ; Cedric Revil ; MSc² ; Charles A. Ngoh ; MSc² ; Johanna Lister ; MSc³ ; Jeong-Mi Kwon ; MSc⁴ ; Mee-Hye Park ; PhD¹ ; Seok-Jin Park ; MSc⁴ ; Young-Suk Park ; PhD ; MD⁵ ; Sang-Joon Shin ; PhD ; MD⁶ ; Myung-Ah Lee ; PhD ; MD⁷ ; Nam-Su Lee ; PhD ; MD⁸ ; Dae-Young Zang ; PhD ; MD⁹ ; Eun-Jin Bae ; MSc¹⁰ ; Mi-Jeong Kang ; BSc¹⁰
• 关键词：antineoplastic combined chemotherapy protocol ; bevacizumab ; colorectal neoplasms ; cost-effectiveness ; indirect comparison ; Republic of Korea
• 刊名：Clinical Therapeutics
• 出版年：2012
• 期刊代码：65_01492918
• 类别：med
• 出版时间：June, 2012
• 卷：34
• 期：6
• 页码：1408-1419
• 文件大小：460 K

摘要

Background

Bevacizumab has been extensively investigated in combination with various standard chemotherapies in the treatment of metastatic colorectal cancer (mCRC). However, a comparison to irinotecan + infusional 5-fluorouracil/leucovorin (FOLFIRI) is lacking.

Objective

To explore clinical effectiveness and cost-effectiveness of adding bevacizumab to a regimen of FOLFIRI for the first-line treatment of mCRC in the Republic of Korea by conducting an indirect treatment comparison.

Methods

A health-economic model was developed to investigate the possible health outcomes (life-years gained [LYG]), direct costs, and incremental cost-effectiveness ratio (ICER) of adding bevacizumab to a FOLFIRI regimen. Data on progression-free and overall survival were derived from randomized clinical trials and were used in the indirect treatment comparison. The annual discount rate for costs and outcomes was 5%. A lifetime horizon of 8 years was used. Sensitivity analyses were carried out on all pivotal model assumptions.

Results

Incremental mean overall survival among patients treated with bevacizumab + FOLFIRI varied between 8.6 and 15.7 months compared with patients treated with FOLFIRI alone. The deterministic base-case result was 1.177 LYG. The discounted ICERs ranged from 渭31.8 to 渭39.5 million/LYG, with the base-case result being 渭34.5 million/LYG. Treatment effect had the most impact on the outcomes in this model.

Conclusions

Although there is no formal threshold for ICER per LYG in Korea, funding may be considered for bevacizumab + FOLFIRI, particularly if the severity and end-of-life nature of mCRC is taken into account.